Novartis Skillfully Rejuvenates Business Amidst Entresto Losses

Pharmaceutical giant Novartis is back on a growth trajectory, skillfully rejuvenating its business despite significant losses from its off-patent heart medication Entresto. The company is expected to face a more turbulent second half of the year on the stock market.